Evidence of BRAFi-induced metabolic plasticity is also observed in BRAFV600 melanoma patients treated with BRAFi, either alone [55] or in combination with MEK inhibitors [57], whereby PGC1α mRNA expression is increased in early-on-treatment melanoma patient samples. Here, MAP2K7 is linked to melanoma.